Top 20 Shareholders December 2017
PAA – Top 20 holders report
Phase II Dog Lymphoma Trial Confirms Monepantel Clinical Benefit
171211_Lymphoma Trial Result_(clean)
PharmAust Raises $1.873m via an Oversubscribed Placement
171206_Capital Raise
Results of AGM 2017
171129_Results of AGM
Trading Halt Request
171201_Trading Halt Request
AGM Presentation 2017
171129_ AGM Presentation
PharmAust Identifies New Proprietary Monepantel-related Compounds With Greater Anti-cancer Activity
171123_Improved potency of MPL analogues_clean
